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Abstract
Progressive multi-focal leukoencephalopathy (PML) is a potentially fatal encephalitis caused by JC polyomavirus (JCV).
PML principally affects people with a compromised immune system, such as patients with multiple sclerosis (MS)
receiving treatment with natalizumab. However, intrathecal synthesis of lipid-reactive IgM in MS patients is associated
with a markedly lower incidence of natalizumab-associated PML compared to those without this antibody repertoire.
Here we demonstrate that a subset of lipid-reactive human and murine IgMs induce a functional anti-viral response
that inhibits replication of encephalitic Alpha and Orthobunyaviruses in multi-cellular central nervous system cultures.
These lipid-specific IgMs trigger microglia to produce IFN-β in a cGAS-STING-dependent manner, which induces an
IFN-α/β-receptor 1-dependent antiviral response in glia and neurons. These data identify lipid-reactive IgM as a
mediator of anti-viral activity in the nervous system and provide a rational explanation why intrathecal synthesis of
lipid-reactive IgM correlates with a reduced incidence of iatrogenic PML in MS.
Keywords: Type-I interferon, Interferon stimulated genes, Viral encephalitis, John Cunningham polyomavirus (JCV),
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Introduction
Neurotropic viral infections pose a major challenge when
considering immune modulatory treatment for patients
with autoimmune diseases. One of the most devastating of
these consequences is progressive multi-focal leukoence-
phalopathy (PML), a rare demyelinating disease caused by
opportunistic infection of the central nervous system
(CNS) by JC polyomavirus (JCV; human polyomavirus 2)
[1, 2]. The seroprevalence of JCV in healthy adults is 40–
80%, but the vast majority of infections are asymptomatic
due to a robust immune response [3, 4].
However, immune-suppressed individuals are at an in-
creased risk of developing PML [5]. This has important
implications for the clinical management of primary and
secondary immune deficiencies, as well as autoimmune
diseases in which immunosuppression is a primary treat-
ment option [4]. The latter include multiple sclerosis
(MS), a chronic inflammatory demyelinating disease of
the CNS [6], in which PML can develop in association
with immunomodulatory disease modifying therapies in-
cluding natalizumab [7] and fumaric acid esters [8].
Natalizumab is a humanised anti-alpha 4 integrin-
specific antibody that significantly reduces disease activity
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by inhibiting migration of immune cells across the blood-
brain barrier (BBB) [9]. However, its use is limited by the
risk of patients developing natalizumab-associated PML,
which in JCV-seropositive patients exceeds 10 per 1000
after a 6 year treatment period [7, 10]. There are no effect-
ive treatments for natalizumab-associated PML, other
than plasma exchange to remove natalizumab from the
circulation. However, as this itself may trigger immune re-
constitution inflammatory syndrome (IRIS) mortality re-
mains high and most survivors are left with severe
neurological deficits [10].
Current efforts to counter the threat posed by
natalizumab-associated PML focus on risk stratification
[10]. This is based primarily on JCV serology, but a re-
port identifying intrathecal synthesis of lipid-specific
IgM antibodies as a factor associated with a lower prob-
ability of developing natalizumab-associated PML sug-
gests an additional strategy [11]. Here, JCV seropositive
patients lacking intrathecal IgM were 60-fold more likely
to develop PML than those positive for lipid-specific
IgM. Importantly, patients positive for both JCV and
intrathecal IgM had similar risk of developing PML as
patients seronegative for JCV, suggesting these anti-
bodies substantially contribute to JCV defences in the
CNS [11]. Inspired by reports that disease-associated
autoantibodies induce expression of type-I interferons
(IFNs) in systemic lupus erythematosus [12], we specu-
lated lipid-reactive IgM might act to enhance antiviral
activity within the CNS.
We now demonstrate that a subset of human and
murine IgM autoantibodies that recognise lipids in the
CNS induce interferon-β (IFN-β) in microglia. This re-
sponse is STING-dependent and mediates IFN-α/β-re-
ceptor 1 (IFNAR1)-dependent antiviral activity in all
major CNS cell types (neurons, astrocytes, oligodendro-
cytes and microglia), as demonstrated by inhibition of
replication of two unrelated encephalitogenic viruses
(Bunyamwera virus (BUNV) and Semliki Forest virus
(SVF)) in myelinating cell cultures. Our data provide a
logical explanation for the observation intrathecal syn-
thesis of lipid-specific IgM is associated with a reduced
incidence of natalizumab-associated PML in MS.
Materials and methods
Myelinated spinal cord cultures from rat
Neurospheres were generated from the striata of post-
natal day 1 Sprague-Dawley rats. Striata were mechanic-
ally dissociated in Leibovitz’s L-15 Medium (Gibco) by
glass Pasteur pipette and cultured in neurosphere media
[Dulbecco’s modified Eagle medium (DMEM)/F12
(Gibco), supplemented with 0.105% NaHCO3, 2mM glu-
tamine, 1% penicillin-streptomycin (Pen/Strep), 5.0 mM
HEPES, 0.0001% bovine serum albumin (BSA), 25 μg/ml
insulin, 100 μg/ml apotransferrin, 60 μM putrescine, 20
nM progesterone, and 30 nM sodium selenite (all from
Sigma)]. Cultures were supplemented with 20 ng/ml re-
combinant murine epidermal growth factor (Peprotech)
and maintained at 37 °C in a humidified atmosphere of 7%
CO2. Cells were fed every 3–4 days by addition of neuro-
sphere medium and EGF. After 7 days, or when cells had
formed large round neurospheres, the neurosphere sus-
pension was centrifuged at 86 rcf for 5 mins and resus-
pended in astrocyte media [DMEM (1 g/ml glucose,
Gibco) supplemented with 10% foetal bovine serum (FBS)
and 2mML-glutamine (both Sigma)] before being plated
onto poly-L-lysine (13 μg/ml) coated cover slips (13-mm
diameter, VWR International). Every 3–4 days, half of the
old media was replaced with fresh astrocyte media until
cells formed a confluent monolayer.
Sprague-Dawley rats were time-mated. At embryonal
development day (E)15.5, spinal cords were extracted
from embryos, meninges removed and placed in 1 ml
Hank’s Balanced Salt Solution (Sigma). Up to 6 cords/ml
were then enzymatically digested with 2.5% trypsin
(100 μl/ml) and 1.33% collagenase (100 μl/ml) (both
Sigma) for 15 mins at 37 °C. Enzymatic activity was
stopped by adding 2 ml of SD inhibitor [L-15 media sup-
plemented with 0.52 mg/ml soybean trypsin inhibitor,
3.0 mg/ml BSA, and 0.04 mg/ml DNase (all Sigma)] per
1 ml HBSS. The cords were then triturated, centrifuged
at 196 rcf for 5 mins, resuspended in plating medium
[50% DMEM, 25% horse serum, 25% Hank’s Balanced
Salt Solution (HBSS)] and plated onto the aforemen-
tioned neurosphere-derived astrocytes at a density of
150,000 cells per coverslip. Coverslips were contained in
35mm Petri dishes, three 13mm coverslips per dish,
and placed in an incubator for 2 h. Cells were topped up
with 450 μl of plating medium and 600 μl of differenti-
ation medium [DMEM (4.5 g/ml glucose), 10 ng/ml bio-
tin, 0.5% N1 supplement, 50 nM hydrocortisone, and
0.1 μg/ml insulin (all from Sigma)]. Cells were fed every
2–3 days by removing 500 μl of old media and replacing
with 600 μl of fresh differentiation media. From DIV13,
cells were fed with differentiation media without added
insulin (DM−).
Myelinated spinal cord cultures from mouse
Myelinating spinal cord cultures were generated from
embryos of a number of mouse strains including; C57/
Bl6 mice (Jackson Laboratories), Ifnar1+/+ and Ifnar1−/−
mice on a 129S7/SvEvBrdBklHprtb-m2 background
(B&K Universal) and Cst+/+, Cst+/− and Cst−/− mice on a
C57/Bl6 background (Prof. Hugh Willison). Mice were
time-mated and pregnant females were killed by CO2
overdose at E13.5. Spinal cords were extracted from em-
bryos and processed as per rat myelinating culture
protocol with some amendments. Cords were enzymati-
cally digested with 2.5% trypsin (100 μl/ml) for 15mins
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at 37 °C. Enzymatic activity was stopped by adding 2ml
SD inhibitor. Cords were triturated, centrifuged at
181rcf and resuspended in plating medium. Cells were
plated onto 13mm diameter glass coverslips coated with
poly-L-lysine (0.1 mg/ml in boric acid buffer, pH 8.4) at
a density of 165,000 cells per coverslip. Coverslips were
contained in 35 mm Petri dishes, 3 coverslips per dish,
and incubated for a minimum of 4 h to attach. Once vis-
ibly attached, dishes were topped up with 300 μl plating
media and 600 μl differentiation media. Cells were fed as
per the rat culture protocol.
Antibody production
Once proliferating at a stable rate, cells were transferred
to a CELLine cell culture flask (BD Biosciences). Cells
were seeded in ultra-low endotoxin media [OptiMem
supplemented with 10% ultra-low endotoxin FBS (VWR)
and 1% Pen/Strep] at a density of 1.5 × 106 cells/ml and
maintained at a density of maximum 1.5 × 106 cells/ml,
supernatants collected and stored at − 20 °C until anti-
body purification. O4 and A4CD antibodies were puri-
fied under sterile conditions from supernatants using
Hi-Trap IgM purification HP columns (GE Healthcare)
as per manufacturer’s instructions. All buffers were
made using sterile ultra-low endotoxin reagents. Eluted
protein was dialysed in a Spectra/Por 6 Regenerated Cel-
lulose Dialysis Membrane (Spectrum Labs) against endo-
toxin tested Dulbecco’s phosphate buffered saline
(Invitrogen) for 24 h at 4 °C. Final antibody concentra-
tion was determined by Nanodrop (Denovix DS-11) and
solution diluted to 1 mg/ml in DPBS.
Antibody treatment
Cultures were treated at day in vitro 24 (DIV24). To treat
cultures, 500 μl of media was removed and 500 μl of treat-
ment added. Treatments were diluted in differentiation
media. All antibodies were used at a final concentration of
20 μg/ml. Antibodies used in treatments included; IgM
from mouse myeloma (Sigma), A4CD, O4, O1 (R&D Sys-
tems or in-house produced), A2B5 (Abcam), rhIgM22,
shIgM22, rhIgM12, shIgM12, shIgM42 and shIgM201
(kindly provided by MR and AW). Untreated controls
were given differentiation media alone. For IFN-β neutral-
isation, DIV24 rat cultures were treated with media alone,
A4CD or O4 in combination with either rabbit anti-rat
IFN-β neutralising antibody or normal rabbit IgG control
(10 μg/ml, R&D Systems) for 24 h.
Virus infections
BUNVGc-eGFP is a recombinant BUNV, in which the
N-terminal 326 amino acid of the viral membrane Gc
glycoprotein was replaced by eGFP [13]. In short, BSR-
T7/5 cells were transfected with 1 μg pT7riboBUNL(+),
pT7riboBUNS(+), and pT7riboBUNMGc-eGFP. After 5
h, growth media [Glasgow Minimum Essential Medium
supplemented with 10% tryptose phosphate broth, 10%
FBS, and (Gibco) and 1mg/ml Geneticin (G418) sulfate
(Calbiochem)]. Cells were incubated for 5–11 days at
33 °C until cytopathic effect was observed. Supernatant
was clarified and stored at − 70 °C until use.
For all eGFP-Semliki Forest Virus (SFV) experiments
we used an eGFP expressing variant of the neurovirulent
strain SFV4. The eGFP marker gene was inserted in
nsP3 via a naturally occurring XhoI site, resulting in
plasmid pCMV-SFV4(Xho-EGFP)4 which was generated
and kindly provided by prof Andres Merits (University
of Tartu). The backbone of this plasmid has been previ-
ously described [14], further details are available from
the Lead Author. Virus stocks were generated by elec-
troporating this plasmid in BHK cells and propagated in
Glasgow Minimum Essential Medium (Gibco) with 5%
FBS, 10% tryptose phosphate broth (Gibco), 1% Pen/
Strep at 37 °C in 5% CO2. When severe cytopathic effect
was observed, virus-containing supernatant was centri-
fuged 500×g for 30 min to remove cellular debris and
cell-free virus stored in small aliquots at − 70 °C. Stocks
were titrated by plaque assay as described below.
DIV24 cultures were treated with either media alone,
A4CD or O4 for 24 h. All media was removed and cells
inoculated with 0.75% BSA (Sigma) in PBS alone or with
BUNV (MOI 1) for 1 h at 5% CO2, shaking gently every
15 min or SFV (MOI 1) for 1 h at room temperature on
a plate shaker. Inoculum was removed and fresh differ-
entiation media was added. Cells were then incubated
for a further 6–24 h, at which point supernatant was col-
lected for plaque assay, cells washed with 0.75% BSA-
PBS and prepared for further analysis.
To quantify virus stocks and production of BUNV,
Vero E6 cell monolayers were incubated with serially di-
luted supernatant for 1 h at 37 °C then covered with
0.6% Avicel (FMC Biopolymer)-minimum essential
medium overlay medium supplemented with 2% FBS.
Cells were incubated for 4 days and fixed with 4%
formaldehyde-PBS and stained with 0.5% (w/v) methyl
violet. Virus titres were calculated and presented as
PFU/ml. A similar assay was used for SFV, with the fol-
lowing adaptations: BHK cells were infected and main-
tained as described, and at 2 days post infection fixed in
10% formaldehyde-PBS and stained with 0.1% toluidine
blue (Sigma).
Drug treatment of cultures
To deplete microglia, rat cultures were treated from
DIV18–28 with PLX3397 (Selleckchem) or an equivalent
volume of dimethyl sulfoxide (DMSO, Sigma) every 2–3
days. Final concentration of PLX3397 in cell culture dish
was maintained at 1 μM and volume of DMSO main-
tained at 0.1% of total media volume. For signalling
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pathway inhibition, DIV24 rat cultures were treated 6 h
with media alone, A4CD or O4 with simultaneous ad-
ministration of either DMSO or 10 μM of one of the fol-
lowing inhibitors; ST2825 (MedChemExpress), RU.521
(Invivogen), C-176 (Biovision) and BX795 (Invivogen).
Fluorescence in situ hybridisation (FISH)
FISH was performed on DIV24 rat myelinating cultures
treated 24 h with either A4CD or O4 using the View-
RNA Cell Plus Assay kit (Invitrogen) as per manufac-
turer’s instructions. First, immunocytochemistry was
performed against the following antigens; GFAP (1:200,
Sigma), NeuN (1:400, Millipore), Olig2 (1:500, Millipore)
and Iba1 (1:500, Wako), using secondary antibodies
AlexaFluor488 goat anti-rabbit IgG and AlexaFluor568
goat anti-mouse IgG1 (both Invitrogen). ViewRNA cell
plus type 6 probe sets against the following genes were
used; Cxcl10, Mx1, Rsad2 and Oasl. Coverslips were
mounted onto glass slides using Mowiol 4–88 mounting
medium. Mounted slides were stored overnight at 4 °C
protected from light and imaged.
RNA isolation
RNA was extracted from rat cultures using the RNeasy
Plus Micro kit (Qiagen) as per manufacturer’s instruc-
tions. RNA was extracted from mouse and virally in-
fected cultures by removing all media from cells, adding
1 ml TRIzol® Reagent per dish and incubating for 10
min. Lysates were transferred to RNase-free tubes (Invi-
trogen) and stored at − 80 °C until use. RNA was isolated
using the PureLink™ RNA Mini Kit (Invitrogen) as per
manufacturer’s instructions. Concentration and quality
of RNA was determined by Nanodrop.
Microarray
RNA from treated DIV24 rat myelinating cultures (mock,
20 μg/ml O4 or IgM isotype control for 24 h) was quality
checked with the Agilent Bioanalyzer 6000 Nano LabChip
platform and biotin labelled using Ambion WT Expres-
sion Kit. The labelled RNA was then hybridized to Affy-
metrix GeneChip Rat Gene 2.1 ST Arrays according to
manufaturer’s instructions using the Fluidics Station 450
and scanned on Gene Array Scanner 3000-7G. Each treat-
ment group (untreated Control, O4 and IgM treatment)
were set up in three replicates, analysed in Partek Genom-
ics Suite (version 6.6, Partek) and deposited in Gene Ex-
pression Omnibus database (https://www.ncbi.nlm.nih.
gov/geo/) under accession number GSE150331. Probe set
level data were normalized using GC-RMA method and
One-Step Tukey’s Biweight method was used to
summarize to transcript cluster level. Differential expres-
sion was then calculated by one-way ANOVA comparing
O4-treatment vs Control, O4-treatment vs IgM-treatment
and IgM-treatment vs Control. Differentially expressed
genes (fold-change > ± 1.4, FDR-adjusted p-value < 0.05)
were then analysed for enriched KEGG pathways using
Partek Pathway and for the presence of interferon regu-
lated genes (IRGs) using the interferome database (v2.01;
http://www.interferome.org/interferome/home.jspx) [15].
cDNA synthesis and quantitative real-time PCR
Primer 3 software (http://biotools.umassmed.edu/bioapps/
primer3_www.cgi) [16] was used to find suitable primer
sequences on mRNA sequences from the NCBI nucleotide
data base, and checked for specificity using BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). cDNA was syn-
thesized from a maximum of 1 μg RNA using a Quanti-
Tect® Reverse Transcription Kit (Qiagen) following the
manufacturer’s instructions using a Biometra T3 Thermo-
cycler (Thermofisher). Synthesised cDNA was diluted to
appropriate volume using RNase-free water (1:200 for
1 μg starting RNA). Quantitative real-time PCR was per-
formed in MicroAmp Fast Optical 96-well reaction plates
(0.1ml) (Invitrogen) with each sample being run in tripli-
cate. Reagents per well were as follows; 7.5 μl Power
SYBR™ Green PCR Master Mix (Applied Biosystems),
5.2ul RNase-free water, 0.3ul primer mix (Integrated DNA
Technologies, 50 μM/primer) and 2 μl cDNA. Plates were
run in an Applied Biosystems Fast Real-Time PCR System
(ABI 7500) and quantified using the comparative CT
(ΔΔCT) method or, for human IgM data alone, standard
curve method. Cycle settings were as follows; 50 °C for 5
min, 95 °C for 10min, followed by 40 cycles of 95 °C for
15 s, 60 °C for 1min, and a final dissociation step at 95 °C
for 15 s. 18S was used as the housekeeping gene for mouse
experiments and virus experiments. Gapdh was used as
the housekeeping gene for all other rat experiments.
Immunocytochemistry
Cultures were fixed with 4% formaldehyde-2% sucrose in
PBS for 10 min. Fixative was replaced by 0.75% BSA-
PBS, and cultures stored at 4 °C until immunocytochem-
istry was performed. Fixed cells were permeabilised with
0.5% Triton X for 10 min, washed with PBS, blocked
with blocking buffer [1% BSA, 10% horse serum in PBS]
for 45 min, incubated with primary antibody diluted in
blocking buffer for 45 min, washed with PBS and incu-
bated in dark with secondary antibody diluted in block-
ing buffer for 15 min. Coverslips were then washed in
PBS followed by dH2O and mounted onto glass slides
with Mowiol 4–88 mounting medium [33% w/v Mowiol®
4–88, 13.2% w/v glycerol (both Sigma), 0.05% v/v DAPI
(Invitrogen) in 0.13M Tris pH 8.5]. Primary antibodies
against the following proteins were used; BUN virions
(1:500, Elliott lab), NeuN (1:400, Millipore), Nestin (1:
200, Millipore), GFAP (1:200, Sigma), Olig2 (Millipore,
1:200), ED1 (1:100, Abcam), Iba1 (1:500, Wako), A4CD,
O4 (both 20 μg/ml, both Linington Lab), O1 (20μg/ml,
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R&D Systems) and A2B5 (20 μg/ml, Abcam). All second-
ary antibodies were purchased from Invitrogen and used
at 1:400 including; AlexaFluor488 goat anti-rabbit IgG,
AlexaFluor488 goat anti-mouse IgM, AlexaFluor568 goat
anti-mouse IgG1 and AlexaFluor568 goat anti-mouse
IgG2a. For live-staining of lipid-specific IgM, live cells
were incubated with antibody (20 μg/ml, 30 min, 4 °C)
and then fixed with 4% PFA. Protocol continues as
above.
Image capture and analysis
All imaging and quantification was performed blind. Cov-
erslips from microglia depletion experiments and BUNV
infections were imaged on an Olympus BX51 microscope
(Olympus Lifescience) using a Retiga R6 camera and Ocu-
lar 2.0 software (both Teledyne Qiamging). Ten images
were taken per coverslip, 3 coverslips per condition for
every biological replicate. Images were saved as 16 bit tif
files and converted to 8 bit png files using CellProfiler [17]
pipeline “Ocular.cpproj”. Total dapi for each png image
was quantified using CellProfiler pipeline “dapi mono.cp”.
Both pipelines can be found at https://github.com/muecs/
cp/tree/v1.1. Iba1-positive cells and BUNV-positive cells
were counted manually using cell counter plugin (https://
imagej.nih.gov/ij/plugins/cell-counter.html) with ImageJ
[18]. Co-localisation of BUNV-positive dapi with other cell
markers was also quantified using the cell counter plugin.
Coverslips from FISH experiments were imaged using
a Zeiss Axio Imager 2 and Zen 2012 (blue edition) soft-
ware. To quantify total dapi, images were saved as png
files using Zen software and processed using the “dapi
mono.cp” CellProfiler pipeline. Cells positive for mRNA
of interest were quantified manually using the cell coun-
ter plugin in Fiji [19]. Co-localisation of mRNA-positive
dapi with other cell markers was also quantified using
the cell counter plugin.
Statistical analysis
Statistical details of experiments including statistical
tests used, n values and what n represents, definition of
centre, dispersion and precision measures are reported
in the figure legends. Statistical significance was deter-
mined using one of the following tests depending on
number of samples and variables; two-tailed t-test for
data with one variable and two conditions, one-way
ANOVA with Tukey’s post hoc test for data with one
variable and greater than two conditions, and two-way
ANOVA with Bonferroni post hoc test for data with two
variables and two conditions. Data were deemed signifi-
cant when p-value was less than 0.05 and are denoted in
figures as *p < 0.05, **p < 0.01, ***p < 0.001. Statistical
analysis was performed in GraphPad Prism 8.
Data availability
The microarray data generated for this study are available
at the GEO repository under the following accession num-
ber GSE150331 and as supplemental information. CellPro-
filer pipelines can be found at https://github.com/muecs/
cp/tree/v1.1
All other data supporting the findings of this study are
available in the article, the Supplementary information
files, or upon request to the authors. We are happy to
provide a source table.
Results
Lipid-specific IgM provides protection against neurotropic
viruses in an IFNAR1 -dependent manner
To test the hypothesis that lipid-specific IgMs induce a
functional anti-viral response in the CNS, we examined
the anti-viral properties of the murine IgM monoclonal
antibody (mAb) O4, recognising sulfatide (3-O-sulfoga-
lactosylceramide), a major target of the intrathecal anti-
body response in MS [20]. The antiviral properties of
this antibody were tested in rodent myelinated cultures,
which replicate much of the cellular and functional com-
plexity of the nervous system in vivo in a tractable
in vitro model [21].
To mimic the situation in MS patients who have intra-
thecal lipid-specific IgM in their CNS before JCV dis-
seminates to the CNS, rat myelinated cultures were pre-
treated for 24 h with O4 or isotype control A4CD, an
IgM mAb specific to myelin oligodendrocyte glycopro-
tein (MOG) peptide. Both were purified in our labora-
tory under the same conditions. As JCV is an obligatory
human pathogen, we used BUNV as an encephalitic
model virus to infect the pre-treated cultures. BUNV, a
prototype for both the orthobunyavirus genus and Peri-
bunyaviridae family, is a tripartite negative sense single-
stranded enveloped RNA virus [22] and can induce se-
vere encephalitis in domestic animals [23].
As the cellular tropism of BUNV in rodents is un-
known this was first mapped by immune fluorescence
microscopy using a GFP-tagged BUNV (BUNVGc-eGFP)
[13] and a panel of cell type specific markers to reveal
that BUNV preferentially infected cells of the neuronal
lineage in myelinating cultures (Fig. 1a, b & i). Pre-
treatment with O4 had a profound antiviral effect as
demonstrated by quantifying BUNVGc-eGFP infected
cells by immune fluorescence microscopy (p < 0.05) (Fig.
1c, d & j). This finding was corroborated when assessing
BUNV RNA expression by RT-PCR, where a > 10-fold
decrease was observed in BUNM transcript in O4-
treated cultures (p = 0.1303) (Fig. 1k).
Considering our myelinated cultures lack adaptive im-
mune cells, we hypothesised that this antiviral effect
might be conferred by the innate antiviral type-I IFN
pathway. To investigate this hypothesis, experiments
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were repeated in myelinated cultures derived from
Ifnar1−/− mice and wild type controls, resulting in a sig-
nificant decrease in BUNVGc-eGFP infected cells and
supernatant viral titre in O4-treated wild type (WT) cul-
tures only, highlighting the dependency of this response
on the type-I IFN pathway (Fig. 1e, f, l & m). Moreover,
this also demonstrates the protective effect of O4 is not
species-specific as it induced a similar level of antiviral
activity to that observed in rat cultures.
To investigate whether this protection can be extended
to other viruses with a different cellular tropism and gen-
erating different Pattern Associated Molecular Patterns
Fig. 1 Lipid-specific IgM provides protection against neurotropic viruses in an IFNAR1-dependent manner. a-d, i-k Rat cultures pre-treated 24 h with
A4CD or O4 and infected with BUNV (MOI = 1). a, b BUNV-infected mature neurons and neuronal progenitor. c, d A4CD and O4-treated cultures
infected with BUNV. i BUNV tropism. j, k Immunocytochemical and RT-qPCR analysis. Data presented as mean ± SEM and analysed by paired two-
tailed t-test. j n = 4 k n = 3. e, f, l, m WT and Ifnar1−/− mouse cultures treated and infected as above. e, f BUNV-infected WT and Ifnar1−/− cultures pre-
treated with O4. l, m Immunocytochemical and plaque assay analysis. Data presented as mean ± SEM, analysed by two-way ANOVA and significant
difference determined by Sidak’s post-hoc test. l WT n = 2, Ifnar1−/− n = 3 m n = 2 for all conditions. g, h, n WT and Ifnar1−/− mouse cultures treated as
above and infected with SFV. g, h SFV-infected mature oligodendrocytes and oligodendrocyte progenitors. n Immunocytochemical analysis. Data
presented as mean ± SEM, analysed by two-way ANOVA and significant difference determined by Sidak’s post-hoc test. n = 4 for all conditions.
Significant differences denoted as *p < 0.05 and ****p < 0.0001
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(PAMPs), we investigated the antiviral potential of O4
using SFV. SFV is an encephalitogenic positive-sense
single-stranded RNA virus that preferentially infects cells
of the oligodendroglial lineage [24] (Fig. 1g & h) (con-
struct kindly provided by Andres Merits). As observed for
BUNV, pre-treatment with O4 inhibited replication of
SFV in WT cultures (p < 0.001), but in this case a residual
protective effect was observed in Ifnar1−/− cultures (p <
0.05) (Fig. 1n). This may be due to steric hindrance of
antibody that is bound to the oligodendrocyte cell surface
restricting viral access and/or disruption of receptor-
mediated endocytosis but nonetheless, the dominant pro-
tective effect is largely IFNAR1-dependent.
Together these results demonstrate that the lipid-
specific IgM mAb O4 exhibits antiviral properties that
can inhibit virus replication in neurons and glia in an
IFNAR1-dependent manner. This supports the idea
that intrathecal lipid-specific IgM found in MS pa-
tients may contribute to protection against JCV and
limit risk of PML.
Lipid-specific IgM induces an antiviral transcriptional
signature in vitro
To gain further insight into the mechanistic basis of this
antiviral response, a microarray was performed on cul-
tures treated for 24 h with O4, IgM isotype control or
media alone. O4 differentially regulated 543 transcripts
compared to the IgM control (431 upregulated, 112 down
regulated; fold-change ≥ ±1.4; FDR-adjusted p ≤ 0.05),
whilst no significant differences were observed between
untreated and IgM control-treated cultures (Fig. 2a,
GSE150331).
The transcriptional response induced by mAb O4 was
characterised by increased expression of multiple genes
that play important roles in the development of antiviral
responses in the CNS (Fig. 2b and Table S1). These in-
clude chemokines (chemotactic cytokines) Cxcl10 and
Ccl5, the products of which co-ordinate recruitment of
immune effector cells into the CNS, [25], as well as nu-
merous genes such as Oasl, Mx1 and Rsad2, which en-
code proteins that restrict viral replication [26]. It is
Fig. 2 Lipid-specific IgM induces anti-viral transcriptional signature in vitro. a, b Microarray analysis of rat myelinating cultures treated 24 h with
media alone, IgM from mouse myeloma (IgM, Sigma) or O4. a Cluster analysis of all significant genes (FDR p-value < 0.05); heat map shows
standardized gene expression level of each gene with high expression in red and low expression in blue. b Bar graph showing genes most
upregulated by O4, interferon stimulated genes denoted by an asterisk. c-g RT-qPCR analysis of rat cultures treated with media alone, IgM, A4CD
or O4 for c 4 h and d, g 24 h. Data analysed by one-way ANOVA and significance determined by Tukey’s post hoc test. IgM (n = 4), A4CD (n = 3)
and O4 (n = 4). Significant differences denoted as *p < 0.05, **p < 0.01 and ****p < 0.0001
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therefore not surprising that pathway enrichment ana-
lysis identified viral diseases as the most significantly
enriched human disease pathways associated with this
response (Table S2). Moreover, the other most signifi-
cantly enriched organismal system pathways included
NOD-like, Toll-like and RIG1-like signaling pathways
(Table S3). These observations led us to speculate the
IFN-like response triggered by O4 involves activation of
one or more Pattern Recognition Receptor (PRR)-
dependent pathways; a concept supported by the dem-
onstration that as much as 72% of all differentially regu-
lated genes are interferon-stimulated genes (ISGs) based
on the murine interferome database (Fig. 2b and Table
S1) [15].
To validate these microarray data, we selected IFN-β
and several top-ranking ISGs for RT-qPCR analysis.
Ifnb1 was rapidly and significantly upregulated within 4
h of O4 treatment (p < 0.01) (Fig. 2c). After 24 h, we ob-
served a significant upregulation of the chemokine genes
Cxcl10 (p = 0.0552) and Ccl5 (p < 0.05), and the antiviral
transcripts Oasl (p < 0.0001), Mx1 (p < 0.01), Rsad2 (p <
0.05), Ifit2 (p < 0.01), Isg15 (p < 0.01), and Isg20 (p < 0.05)
(Fig. 2d-g and Suppl. Fig. 1A-D) compared to the IgM
and untreated controls.
In summary, these data demonstrate that O4 induces
an “IFN-like” response in CNS cells, explaining the po-
tent antiviral effect of O4 against two genetically distinct
neurotropic model viruses.
The response induced by O4 is IFN-β- and IFNAR-
dependent
To investigate the importance of IFN signalling for this
response, we first mapped the kinetics of IFN and ISG
expression induced by O4. Expression of Ifnb1 was de-
tected after 4 h, peaked at 8 h and then declined slowly
over the following 10 h (Suppl. Fig. 2A). In contrast, ISG
expression increased markedly between 8 and 18 h post-
treatment (Suppl. Fig. 2B-H). Induction of Ifnb1 and
these selected ISGs was not observed in cultures treated
with control IgM (Fig. 2c-g).
To assess whether the O4 response was dependent on
type-I IFN signalling, WT and Ifnar1−/− mouse myeli-
nating cultures were treated with media alone, control
IgM (A4CD) or O4 for 24 h. Induction of ISGs by O4
was abrogated almost completely in Ifnar1−/− cultures,
showing a significant interaction between the presence
of Type I IFN receptors and upregulation of Cxcl10 (p <
0.0001), Mx1 (p < 0.01), Rsad2 (p < 0.001) and Oasl (p <
0.001) (Fig. 3a-d). Induction of ISGs by O4 is therefore
mediated predominantly via activation of the type-I IFN
pathway.
To confirm the ISG induction was specifically IFN-β-
dependent as indicated by the mRNA expression data
(Suppl. Fig. 2A), rat myelinating cultures were treated
for 24 h with A4CD or O4 in the presence of an IFN-β
neutralising antibody or rabbit IgG as a control. O4-
induced ISG expression was attenuated significantly in
the presence of the IFN-β neutralising antibody with sig-
nificant interaction between treatment and neutralisa-
tion being observed for mRNA expression of Cxcl10
(p < 0.05), Mx1 (p < 0.05) and Rsad2 (p < 0.05) (Fig. 3e-
g). Expression of OasI was also reduced when IFN-β was
neutralised but this did not reach statistical significance
(p = 0.1072) (Fig. 3h).
These data confirm O4-mediated induction of IFN-β
is responsible for IFNAR1-dependent expression of anti-
viral ISGs in these CNS cultures, an observation
supporting our hypothesis intrathecal synthesis of lipid-
specific IgMs can have antiviral properties in the CNS.
Microglia are the major source of Ifnb1 in a cGAS-STING-
dependent manner
To further elucidate the mechanism of action by O4, we
sought to identify those cells responsible for producing
IFN-β. Previous studies indicate microglia are a major
source of IFN-β [27, 28] and may therefore orchestrate
ISG expression in other neural cells. We therefore used
the colony-stimulating factor 1 receptor (CSF-1R) inhibi-
tor PLX3397 to deplete microglia prior to treating the
cultures with O4 or control IgM [29]. PLX3397 reduced
Iba-1+ microglia by > 99% without affecting viability of
the other cell types (Fig. 3i-l). This was accompanied by
an almost complete abrogation of Ifnb1 expression in
O4-treated cultures (Fig. 3m). We therefore conclude
microglia are the major source of O4-induced Ifnb1 ex-
pression in myelinating cultures.
To gain understanding as to how O4 upregulates IFN-
β in microglia, we screened a panel of inhibitors that act
upstream of known IFN-β-inducing pathways. Rat mye-
linated cultures were treated for 6 h with O4 combined
with vehicle or inhibitor of interest (10 μM). Ifnb1 ex-
pression was substantially depleted in cultures where
cGAS (RU.521) or STING (C-176, p < 0.05) were inhib-
ited, and completely ablated by inhibition of TBK1/IKKε
(BX795, p < 0.05) (Fig. 3n). This would suggest that Ifnb1
after O4 treatment is upregulated predominantly by a
cGAS-STING-TBK1/IKKε dependent pathway.
O4 induces cell type specific patterns of ISG expression in
the CNS
Having identified microglia as the major source of
IFN-β, we next asked if IFN-β expression orchestrates
ISG expression across all major CNS cell types. For
many ISGs there are no suitable antibodies commer-
cially available, so we combined Fluorescent In Situ
Hybridisation (FISH) with cell-specific antibodies to
visualise transcripts encoding candidate ISGs (Cxcl10,
Mx1, Rsad2 and Oasl) in neurons, oligodendroglia,
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Fig. 3 O4 response is mediated by Ifnar1 and microglia-derived interferon-β in a cGAS-STING-TBK1-IKKε dependent manner. a-h RT-qPCR analysis
of ISG expression in a-d WT and Ifnar1−/− mouse cultures treated 24 h with A4CD or O4 and e-h rat cultures treated 24 h with A4CD or O4 in
combination with rabbit IgG or anti-rat IFN-β neutralising antibody. Data presented as mean fold change compared to untreated control ± SEM,
analysed by two-way ANOVA, significant interaction denoted *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. WT (n = 2), Ifnar1−/− (n = 4), IFN-
β neutralisation experiment (n = 3 all conditions). i-m Rat cultures treated 10 days with DMSO or PLX3397 followed by 6 h treatment with A4CD
or O4. i, j Iba1 staining. k, l Iba1+ and DAPI+ cells. Data presented as mean ± SEM, significant difference determined by paired two-tailed t-test,
*p < 0.05. m RT-qPCR analysis of Ifnb1 expression. Data presented as mean fold change compared to untreated control ± SEM, analysed by two-
way ANOVA, significant interaction denoted *p < 0.05, n = 3 for all conditions. n Ifnb1 expression in rat cultures treated 6 h with O4 alone or in
combination with vehicle or inhibitor of interest (10 μM). Data presented as mean fold change compared to untreated control ± SEM, analysed
by one-way ANOVA with Tukey’s post hoc test. Significant difference compared to O4 alone denoted as *p < 0.05. O4 alone (n = 6), DMSO (n = 6),
ST2825 (n = 3), RU.521 (n = 2), C-176 (n = 5) and BX795 (n = 3)
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astrocytes and microglia. Compared to A4CD-treated
controls, O4 induced a significant increase in cells ex-
pressing these candidate ISGs (Cxcl10 p < 0.001; Mx1
p < 0.001; Rsad2 p < 0.001 and Oasl p < 0.01) (Suppl.
Fig. 3) and each cell type upregulated at least one
ISG (Fig. 4a). Astrocytes upregulated all four ISGs,
neurons upregulated Rsad2, Cxcl10 and Mx1, oligo-
dendrocytes upregulated Cxcl10 and Mx1 whilst
microglia only upregulated Oasl in this model of the
CNS (Fig. 4).
These observations reinforce our hypothesis that
intrathecal synthesis of lipid-specific IgM protects
MS patients from natalizumab-associated PML and
presumably other viral infections of the CNS.
Lipid-specific IgM-mediated antiviral responses are not
sulfatide dependent
We next asked if the STING-dependent induction of
IFN-β is dependent on O4 binding sulfatide; a galacto-
sphingolipid highly enriched in myelin. O4 is poly-
reactive and not only binds sulfatide but also seminolipid
(3-sulfogalactosyl-1-alkyl-2-acyl-sn-glycerol) and a var-
iety of other ligands [30]. To differentiate between these
targets we used cerebroside sulfotransferase (CST) defi-
cient mice that lack the ability to synthesise sulfatide
and seminolipid [31], resulting in CST−/− cells to which
O4 cannot bind (Fig. 5a & b).
Comparison of cultures from CST+/+, CST+/− and
CST−/− embryos revealed that specific binding of O4 to
Fig. 4 O4 induces cell type specific patterns of ISG expression in the CNS. a-i DIV24 rat cultures treated 24 h with A4CD or O4. a Table showing
differential cellular expression of ISGs. Data analysed by paired two-tailed t-test. Significant differences denoted by *p < 0.05 and **p < 0.01. n = 3.
b, c GFAP (astrocytes) and Cxcl10 in A4CD and O4-treated cultures respectively. (d, e) NeuN (neurons) and Rsad2 in A4CD and O4-treated cultures
respectively. f, g Olig2 (oligodendrocytes) and Mx1 in A4CD and O4-treated cultures respectively. h, i Iba1 (microglia) and Oasl in A4CD and O4-
treated cultures respectively
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Fig. 5 (See legend on next page.)
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sulfatide, seminolipid or any other CST-dependent sulfo-
glycolipid exposed at the outer surface of myelin and oli-
godendrocytes was not required for O4 induction of Ifnb
(Fig. 5a-c). Whilst O4-indued Ifnb expression by CST−/−
cultures was lower for CST+/+ cultures, this difference
did not reach statistical significance and could be due to
the lower percentage of microglia in the CST−/− cultures
(data not shown). Recognition of cell surface sulfogalac-
tolipids by O4 is therefore not an absolute requirement
to trigger induction of Ifnb1. This was unexpected as
our working hypothesis was that induction of antiviral
activity involved damage associated molecular patterns
(DAMPs) generated in response to O4 binding to the
oligodendrocyte/myelin surface.
This observation prompted us to explore whether
other glycosphingolipid-reactive IgM mAbs would also
induce Ifnb1 expression in this culture system. This was
investigated using O1 which is specific for galactosyl cer-
amide [32] and A2B5 which recognises multiple c-series
gangliosides [33]. Immunofluorescence staining con-
firmed O1 bound extensively to oligodendroglia and
myelin (Fig. 5f), whilst A2B5 weakly labelled a popula-
tion of cells identified tentatively as neural progenitors
(Fig. 5g). Strikingly, we found A2B5 upregulated expres-
sion of Cxcl10 and Mx1 to levels comparable to that in
O4 treated cultures, whereas O1 had no such effect (Fig.
5h & i). These data indicate induction of antiviral activ-
ity by lipid-reactive IgM is not restricted to O4 but can
be mediated by other lipid-reactive IgMs and does not
require recognition of CNS myelin.
Screening of human-derived IgM antibodies identifies
candidate with antiviral properties
To determine if IgMs with antiviral activity are present
in the human antibody repertoire, we investigated a
small panel of human IgMs isolated from patients with
IgM gammopathies such as Waldenstrom’s macroglobu-
linemia [34]. Using mouse myelinated cultures, we found
three out of six tested antibodies induced expression of
Ifnb1 at 2 h (Fig. 5j) and Cxcl10 at 24 h (Fig. 5k);
shIgM22 (1), 2) rhIgM22 (2) which is a recombinant ver-
sion of shIgM22 and to a far lesser extent shIgM42 (5).
To assess whether induction of Ifnb1 supported a func-
tional antiviral response we pre-treated cultures with
human IgMs for 24 h and then infected them with SFV.
We observed a substantial decrease in the percentage of
cells infected with SFV in cultures pre-treated with
rhIgM22 and to a lesser extent shIgM22 (Fig. 5l); an ef-
fect that correlates with their ability to induce Ifnb1. Im-
munofluorescence staining showed these two antiviral
antibodies also bind oligodendrocytes (Suppl. Fig. 4A &
B) whilst the remaining antibodies in this screen target
neurons (Suppl. Fig. 4C-E) or failed to bind in culture
(Suppl. Fig. 4F).
Together, the data indicate a subset of lipid-specific
IgM antibodies exists in mice and humans that can in-
duce a functional antiviral response in the CNS. This
previously unreported mechanism offers an explanation
for the association between intrathecal lipid-specific IgM
and protection against JCV in MS patients.
Discussion
Sustained intrathecal antibody synthesis is the most con-
sistent and well-documented immunological abnormality
associated with MS; its most obvious manifestation be-
ing the presence of oligoclonal immunoglobulins in pa-
tient cerebrospinal fluid [35]. The specificity profile of
this response is complex, but contains a significant com-
ponent directed against lipid antigens in particular sulfa-
tide (3-O-sulfated galactosyl ceramide) [20, 36, 37]. It
has been suggested this lipid-specific antibody response
plays an important role in modulating disease activity in
the CNS as intrathecal synthesis of lipid-reactive IgM
correlates not only with a more aggressive disease course
[38], but also a reduced risk of patients developing
natalizumab-associated PML [11]. Inspired by the latter
report, we hypothesised a subset of lipid-reactive IgMs
might enhance innate antiviral activity in the CNS. We
now demonstrate that several different lipid-reactive
IgM mAbs can initiate a functional antiviral response in
primary myelinating cultures that reproduce the cellular
and functional complexity of the CNS [21, 39]. This re-
sponse is dependent on cGAS/STING-mediated upregu-
lation of IFN-β in microglia, which then triggers IFNA
R1-dependent expression of antiviral ISGs in oligoden-
drocytes, neurons, astrocytes and microglia.
Identification of microglia as the source of IFN-β in-
duced by O4 concurs with studies demonstrating
(See figure on previous page.)
Fig. 5 Lipid-specific IgM mediated antiviral responses are not sulfatide-dependent and identification of similar antibodies in human repertoire. a,
b O4 staining in WT and Cst−/− mouse cultures respectively. c Ifnb1 expression in DIV24 Cst+/+, Cst+/− and Cst−/− cultures treated 6 h with A4CD or
O4. Data presented as mean fold change compared to untreated control ± SEM and analysed by two-way ANOVA. d-g Representative images of
binding patterns of A4CD, O4, O1 and A2B5 in DIV24 rat cultures. h, i ISG expression in DIV24 rat cultures treated 24 h with A4CD, O4, O1 and
A2B5. Data presented as mean fold change compared to untreated control ± SEM and analysed by one-way ANOVA with Tukey’s post hoc test.
Significant difference compared to A4CD denoted as *p < 0.05, n = 3 for all conditions. j-l Screening of patient-derived human IgM antibodies
(hIgM’s) j Ifnb1 expression 2 h post-treatment. k Cxcl10 expression 24 h post-treatment. Data represent two technical replicates from one
biological n (DIV24 mouse cultures) and are presented as mean ± SD. l Immunocytochemical analysis of DIV24 mouse cultures pre-treated 24 h
with hIgM’s and infected with SFV. Data presented as mean ± SD and represent a biological n of 2 for all conditions except sample 3 (n = 1)
Hayden et al. Acta Neuropathologica Communications           (2020) 8:135 Page 12 of 16
microglia are major producers of IFN-β in other inflam-
matory and viral disease models [27, 28, 40]. IFN-β sub-
sequently upregulated expression of ISGs in surrounding
neurons and glia via activation of IFNAR, which is
expressed ubiquitously by cells throughout the CNS
[41]. However, the response of individual cells to IFN-β
will differ due to intrinsic differences in signalling
thresholds and basal levels of proteins regulating the
downstream response [42, 43]. Indeed, our comparative
analyses of four selected ISGs that are upregulated in re-
sponse to O4 indicates astrocytes are especially efficient
at responding to microglia-derived IFN-β (Fig. 4a).
Astrocytes are the major glial cell type of the CNS and
together with microglia are integral components of the
BBB [44]. For viruses that enter the CNS by crossing the
vascular endothelium, astrocytes are the first cells these
viruses encounter. The robust astrocytic response to
microglia-derived IFN-β may therefore represent a crit-
ical “gate keeper” function that helps protects the CNS
compartment from systemic infections [45, 46]. How-
ever, our data demonstrate O4 not only initiates antiviral
activity in astrocytes but also in oligodendrocytes and
neurons. This is important as JCV infects all three cell
types in PML [47, 48], and supports our hypothesis that
a subset of lipid-reactive IgMs enhance antiviral activity
in the CNS, protecting MS patients from natalizumab-
associated PML. We were unable to confirm this directly
as JCV is an obligate human pathogen. Nonetheless, our
identification of human IgMs with similar antiviral prop-
erties, together with reports that IFN-β inhibits JCV rep-
lication in human glia [49, 50] support this concept.
In addition to providing a logical mechanism linking
intrathecal synthesis of lipid-reactive IgM with protec-
tion from natalizumab-associated PML [11], our data
also provide new insight into why this antibody response
is also associated with a more aggressive MS disease
course [38]. In addition to inducing multiple antiviral
genes, O4 also upregulated expression of a large number
of chemokine genes (Fig. 2b, Table S1). Chemokines are
important regulators of immune cell migration and play
key roles in the development of inflammatory responses
in the CNS [51]. We therefore interpret this transcrip-
tional response as a mechanism to recruit immune cells
across the BBB in response to a perceived viral threat.
The observed chemokine response is mainly involved
in recruitment of T and B cells, and monocytes, all of
which can mediate tissue damage in neuroinflamma-
tory diseases [52–57]. This multifaceted cellular re-
sponse is predicted to accelerate clearance of viral
pathogens, but in the context of MS may enhance in-
flammatory activity in the CNS, resulting in a more
aggressive disease course.
This is perhaps surprising as IFN-β is a well-
recognised treatment for MS. However, we attribute this
apparent dichotomy to marked differences in the bio-
logical effects of local, endogenous production of IFN-β
within the CNS as opposed to those induced by systemic
treatment in the periphery. Our data indicate induction
of IFΝ-β by interferogenic IgM’s stimulates a co-
ordinated but sequestered antiviral response in the CNS
that includes a pro-inflammatory component predicted
to enhance disease activity in MS. In contrast, the mech-
anisms responsible for the therapeutic efficacy of IFN-β
in MS remain poorly understood. It is unclear if sys-
temic treatment with IFN- β also triggers antiviral activ-
ity in the CNS, but its mode of action include effects
that reduce leukocyte migration across the blood brain
barrier [58–60]. This is the same mechanism by which
natalizumab suppresses immune surveillance of the
CNS, a major factor contributing to the risk of patients
developing PML. As such, this may explain why some of
the first cases of natalizumab-associated PML occurred
in MS patients undergoing combinatorial treatment with
IFN-β [61, 62].
Whilst PML is relatively rare, many other viruses cause
life-threatening infections of the CNS, the prevalence of
which is increasing due to the continuing emergence of
encephalitogenic viruses [63, 64]. Moreover, in over half
of presumptive cases of viral encephalitis the causative
agent is never identified [65], and for most viral patho-
gens there are no effective antivirals available, as a con-
sequence the clinical outcome is often poor [66]. Pan-
viral therapeutic strategies that boost innate antiviral ac-
tivity in the CNS rather than attempting to target the
causative agent specifically may therefore transform
treatment of these diseases. Activating skin macrophages
at the inoculation site provides pan-viral protection
against mosquito-transmitted viruses [67], suggesting a
similar outcome might be achieved within the CNS by
activating microglia. It would be of interest to determine
whether the presence of intrathecal lipid-reactive IgM is
correlated to differences in the incidence of complica-
tions due to other viruses in the nervous system. Our
data obtained using BUNV and SFV as genetically unre-
lated, model neurotropic viruses support this concept,
but there are major challenges associated with using
lipid-reactive IgMs to stimulate microglial responses in
the CNS.
Challenges of therapeutic use of IgMs include the po-
tential risk of neurological deficits caused by antibodies
that can bind to the myelin/oligodendrocyte surface [36,
68] and the difficulty achieving sustained high concen-
trations of IgM in the CNS compartment [69, 70].
Miniaturization of intrathecal pumps may overcome the
latter problem, but to develop a safe and more generally
accessible pharmacological treatment strategy we must
understand how lipid-specific IgMs induce expression of
IFN-β in the CNS.
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We initially focused on the role of antibody-specificity,
as this is the primary factor determining the functional
activity of somatically mature antibodies. However, those
IgMs inducing an antiviral effect in the CNS are close to
germline and polyreactive, features indicating they are
natural antibodies [71]. As yet no common reactivity
was identified that would account for the ability of O4,
A2B5 and rhIgM22 to induce IFN-β in the CNS. O4 rec-
ognizes sulfatide, seminolipid and other targets [30],
A2B5 binds multiple c-series gangliosides [72] and
rhIgM22 binds one or more unidentified ligands [73].
Notably, O4 and hIgM22 are both natural IgMs with few
somatic mutations and we hypothesise their polyreactiv-
ity underlies their ability to induce IFN-β in myelinated
cultures. Our finding that neither sulfogalactolipids (Fig.
5a-c) nor binding to myelin/oligodendrocytes (Fig. 5f-i)
are prerequisites to trigger IFN-β expression by micro-
glia suggest cellular specificity is not a major factor de-
termining their activity. Based on these observations and
our demonstration IFN-β induction by O4 involves acti-
vation of a cGAS-STING-TBK1/IKKε dependent path-
way, we are currently exploring the hypothesis that
interferogenic IgMs enhance delivery of an endogenous
cGAS/STING agonist to microglia. A precedent which is
provided by studies demonstrating that immune com-
plexes can induce type I IFN expression in plasmacytoid
dendritic cells by enhancing delivery of host nucleic
acids [74, 75].
Conclusion
In conclusion, we identify a logical mechanism to ex-
plain the association between intrathecal synthesis of
lipid reactive IgM and decreased incidence of
natalizumab-associated PML in MS. This strengthens
the case for using the presence of intrathecal lipid-
specific IgM for further risk stratification when decid-
ing on treatment regimens for MS patients. Further-
more, we hope this mechanism can be exploited to
guide development of pan-viral treatment strategies
for viral encephalitis.
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